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Abstract: Breast cancer is the most common cause of cutaneous metastases from internal 
malignancies. Generally, the neoplastic cells are located in the dermis or hypodermis, while 
a finding of transepidermal elimination on cutaneous metastases is exceptional. In this report 
we present a patient with perforating cutaneous metastases from breast cancer with mucin 1 
expression. Cutaneous, bone, lung, and hepatic lesions were detected two years after the diag-
nosis of the primary tumor.
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Introduction
Cutaneous metastases are defined as dermal or hypodermal neoplastic tissue that has 
no contiguity with the primary tumor. Skin metastases from internal neoplasms are an 
uncommon clinical finding with an overall incidence of 5.3% and the most common 
cause is breast cancer with an incidence of 23.9%.1
In general, skin metastases of breast cancer affect the dermis and histologically 
appear as malignant ductal epithelial cells in sheets, cords, glands, or are arranged in a 
diffuse infiltrate.2 The finding of transepidermal elimination on cutaneous metastases is 
exceptional and has only been reported in a few cases.3,4 Mehregan classified transepider-
mal elimination into three types, and the elimination of dermal tumor nests corresponds 
to type 3 which involves an active interaction between epidermis and dermal connective 
tissue.5 Although transepidermal elimination is the histological feature of the classical 
perforating disorders, it is also described in other cutaneous conditions and in tumors 
such as melanocytic nevus,6 eccrine poroma,7 malignant melanoma,8 pilomatricoma,9 
and metastatic carcinoma.3,4 In this report we present a case of perforating cutaneous 
metastasis from breast cancer with mucin 1 (MUC1) expression.
Case report
In February 2010, a 48-year-old Argentine woman had undergone tumorectomy in 
her left breast with diagnosis of an invasive ductal carcinoma with low nuclear and 
histological differentiation grades; estrogen (ER) and progesterone (PR) receptors were 
negative and Her2/neu was positive. In September 2011, a mastectomy with immedi-
ate breast reconstruction was performed due to local tumor recurrence and the patient 
received systemic chemotherapy. In March 2012, she consulted because  multiple skin 
nodules had appeared 3 months before. Lung, bone, and hepatic metastases were also 
detected.
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Physical examination revealed an erythematous nodule 
that was 4 cm in diameter, polylobulated, and with ulcerated 
surface on the chest region. Multiple erythematous painful 
nodules from 5 mm to 2 cm were distributed on her chest 
and over the reconstructed breast (Figure 1).
A skin biopsy of one of the small lesions revealed skin 
metastasis from breast carcinoma (ER-PR-Her2/neu+). 
 Histopathologically, tumor cell nests were seen in the dermis. 
By immunohistochemistry, MUC1 expression was studied 
and a strong reaction was found with a mixed pattern at 
the plasma membrane and in the cytoplasm (Figure 2). 
Some epidermal cells at the Malpighi stratum also showed 
cytoplasmic positive staining. Tumor cells in the papillary 
dermis appeared to penetrate through the epidermis, sug-
gesting transepidermal elimination. The epidermis showed 
no signals of ulceration (Figure 3), and in some malignant 
cells, a MUC1 moderate reaction was found.
Discussion
Cutaneous metastases from breast carcinoma usually 
appear months to years after the diagnosis and treat-
ment of the primary malignancy.10,11The most common 
localizations are in the chest wall and abdomen, but they 
can also be found in the scalp and extremities.10 The 
clinical presentations vary over a wide range of different 
patterns. Nodules are the most common manifestation 
(80%), followed by telangiectatic carcinoma (11%), ery-
sipeloid carcinoma (3%), “en cuirasse” carcinoma (3%), 
alopecia  neoplastica (2%), and a zosteriform type (0.8%).12 
A diagnosis of cutaneous metastases is based on the clinical 
manifestations and the histopathologic study of the lesions. 
 Histopathologically, cutaneous metastatic nodules show 
malignant cells in the dermis arranged in nests surrounded 
with desmoplastic stroma.2 In our patient, clinically, the 
skin lesions were nodules, but histologically, tumor cells 
were not restricted to dermal nests since they also showed 
perforation and transepidermal elimination.
Altered structures of the dermis and foreign material like 
neoplastic cells or external substances can be removed from 
the dermis by different mechanisms. Mehregan5 classified 
transepidermal elimination into three types which differ in 
the mechanism of removal. In type 1, nonmotile cells or small 
particles, which produce minimal or no dermal reaction, can 
be caught between keratinocytes and carried to the epidermis 
surface during corneocyte differentiation. In type 2, motile 
cells or microorganisms actively migrate into the epidermis 
and are subsequently eliminated with normal desquamation 
Figure 1 an ulcerated metastatic nodule on the chest region is observed.
Note: other metastatic lesions over the chest and reconstructed breast are also 
present.
Figure 3 Breast cancer cutaneous metastasis.
Notes: tumoral malignant cell nests passing through the epidermis are observed. 
Mucin 1 expression is found at the epidermal borders and at the tumor cells. the 
pattern of expression is cytoplasmic.
Figure 2 Microphotograph of immunoperoxidase staining of a metastatic cutaneous 
lesion of the patient.
Notes: Neoplastic cells in the dermis show a strong reaction with anti-mucin 
1 monoclonal antibody (HMFG1 monoclonal antibody) with a mixed pattern.
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similar to type 1. Type 1 and type 2 are passive processes 
and have been termed “transmigration.” Type 3 involves 
epithelial–dermal interaction with active elimination of the 
foreign material through the epidermis.
The phenomenon of transepidermal elimination occurs in 
certain dermatoses in which altered structures of the dermis 
and foreign substances induce an inflammatory response 
causing the release of collagenases, elastases, and proteases. 
This inflammatory response generates alteration of the 
matrix with necrosis and perforation, and can also stimulate 
pseudoepitheliomatous hyperplasia of the epidermis and 
subsequent formation of transepidermal perforating canals 
with elimination of the dermal material.4,5
In a case reported by Ohnishi et al,3 breast cancer cutane-
ous metastases with transepidermal elimination presented 
with epidermotropism of neoplastic cells and pagetoid 
spread, features that our patient did not show. On the other 
hand, Abbas et al4 published a case of perforating cutane-
ous metastasis from an ovarian carcinoma which showed 
malignant cells in the dermis and hypodermis with areas of 
transepidermal elimination without epidermotropism. Immu-
nohistochemical staining of the tumor cells was positive for 
MUC1, as we report in our case.
Almost all breast cancer cells express MUC113–16 although 
benign breast neoplasms and normal breast cells express this 
mucin as well.17,18  It is considered that MUC1 nonapical 
expression, as well as its overexpression, are the hallmarks 
of MUC1 reactivity in breast cancer cells.19
Although contradictory results have been found between 
MUC1 expression and survival in breast cancer patients, 
more than 70% of studies on tumor samples have found that 
the presence of any MUC1 in the majority of tumor cells is 
associated with an improved prognosis.20 In relation to subcel-
lular localization of MUC1, it has been observed that patients 
with tumors with the lineal (membrane) pattern have better 
survival.21 –23 Rahn et al20 reported that aberrantly localized 
MUC1 in the tumor cell cytoplasm or nonapical membrane 
is associated with a worse prognosis. In a previous report, 
we found a significant decrease of MUC1 apical expression 
frequency according to histological as well as nuclear grade 
increment. In this sense, it is known that histological grade 
is an accurate predictor of tumor behavior.24 The presence of 
apical membrane staining would indicate that MUC1 target-
ing pathways are intact, and it has been associated with better 
prognosis that is possibly related to functional differentiation 
of the tumor.24 Rahn et al20 also found a significantly lower 
mean nuclear grade in tumors with high MUC1 expression 
(50%). Coincidentally, in the primary tumor of our patient, 
a high nonapical MUC1 expression along with low nuclear 
and differentiation grades was observed.
MUC1 may alter the interaction between tumor cells and 
their environment, changing the composition. It has been 
observed that MUC1 cytoplasmic tail interacts with β-catenin 
through a similar motif to that found in E-cadherin and 
inhibits the formation of an E-cadherin-β-catenin complex, 
reducing cell–cell adhesion.19
Similar to Abbas et al,4 it is possible that in our case, the 
contributing factors to transepidermal elimination could be 
related to a tumor–dermis interaction in which the epidermis 
does not seem to be implicated. The physical effect by the 
expanding tumor and the inflammatory response are factors to 
be considered. Also, the possibility of a vascular compromise 
resulting in necrosis and ulceration of the epidermis as well 
as MUC1 expression may play a role.
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